Pfizer’s Xeljanz (tofacitinib) was the first JAK inhibitor ... including Gilead Sciences’ filgotinib and AbbVie’s upadacitinib. These are being developed for RA in the first instance ...
with the risk of heart-related issues leading to warnings being applied to the labels of Olumiant and other drugs in the class including Pfizer's Xeljanz (tofacitinib) and AbbVie's Rinvoq ...
These approvals, combined with four other drugs approved for JIA during 2020-2023 (tofacitinib, golimumab, secukinumab, and ustekinumab), represent an “exponential rise” over the prior two dec ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback